Amgen eyes expansion and acquires Turkish generics firm

Article Date: 26/04/2012 08:11
Amgen eyes expansion and acquires Turkish generics firm

Vacancy Search

Quick job search

Advanced Search

Latest News

UK will trial stem cell/gene therapy in lung cancer

UK will trial stem cell/gene therapy in lung cancer

NICE backs BMS/Pfizer bloodthinner Eliquis for VTE

NICE backs BMS/Pfizer bloodthinner Eliquis for VTE

Gates Foundation sinks $52m into CureVac

Gates Foundation sinks $52m into CureVac

OPINION by Dr Phil Hammond: Can I trust this doctor?

OPINION by Dr Phil Hammond: Can I trust this doctor?

Mallinckrodt buys Ikaria for $2.3bn

Mallinckrodt buys Ikaria for $2.3bn

AbbVie buys Pharmacyclics for $21bn

AbbVie buys Pharmacyclics for $21bn

Eisai and Merck in cancer combo deal

Eisai and Merck in cancer combo deal

Baxter makes a move on immunology with SuppreMol play

If the sector was wondering where Baxter International’s biopharma spin-off would focus, yesterday’s €200m ($221m) buyout of SuppreMol gave a pretty big clue.

FDA surprises everyone with super-fast Opdivo lung cancer approval

For those harbouring concerns about regulators’ abilities to keep up with drug makers’ rapid progress in proving the potential of the anti-PD-1 antibodies, the super-fast US approval of...

A few unsung heroes from AbbVie’s desperate $21bn move

The clear winners from yesterday’s shock takeout of Pharmacyclics are the group’s management, which played a blinder in more ways than one, and investors who had – seemingly against reason –...
more news